Vectura Group PLC (VEC) Insider Acquires £41,400 in Stock
Vectura Group PLC (LON:VEC) insider Andrew Derodra purchased 30,000 shares of Vectura Group PLC stock in a transaction dated Friday, September 30th. The shares were purchased at an average price of GBX 138 ($1.80) per share, with a total value of £41,400 ($54,039.94).
Shares of Vectura Group PLC (LON:VEC) traded down 2.06% during mid-day trading on Friday, reaching GBX 138.10. The company had a trading volume of 604,494 shares. The stock’s market capitalization is GBX 567.06 million. The firm’s 50 day moving average is GBX 139.23 and its 200-day moving average is GBX 155.59. Vectura Group PLC has a 12-month low of GBX 122.90 and a 12-month high of GBX 200.10.
Several research firms recently weighed in on VEC. Numis Securities Ltd boosted their target price on Vectura Group PLC from GBX 246 ($3.21) to GBX 252 ($3.29) and gave the stock a “buy” rating in a report on Monday, September 19th. Peel Hunt restated a “buy” rating and issued a GBX 200 ($2.61) target price on shares of Vectura Group PLC in a report on Monday, September 5th. Stifel Nicolaus restated a “buy” rating and issued a GBX 242 ($3.16) target price on shares of Vectura Group PLC in a report on Tuesday, August 30th. FinnCap restated a “buy” rating and issued a GBX 225 ($2.94) target price on shares of Vectura Group PLC in a report on Tuesday, August 30th. Finally, Citigroup Inc. restated a “buy” rating and issued a GBX 215 ($2.81) target price on shares of Vectura Group PLC in a report on Thursday, July 28th. Eight equities research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus price target of GBX 222.25 ($2.90).
Vectura Group PLC Company Profile
Vectura Group plc is a product development company. The Company focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). The Company has eight products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to pharmaceutical companies.
Receive News & Stock Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related stocks with our FREE daily email newsletter.